Whole-exome and whole-genome sequencing in chronic lymphocytic leukemia: new biomarkers to target.

Abstract excerpt

Many biomarkers indicate prognosis in chronic lymphocytic leukemia; such as fluorescence in situ hybridization testing: 17p or 11q deletions have a worse prognosis than trisomy 12, 13q deletion or normal result, or the mutational status of the immunoglobulin heavy chain (IGHV): unmutated IGHV have a worse prognosis than mutated IGHV. Recently, many gene mutations (TP53, NOTCH1 etc.,) have been linked to a worse...

Topics

Join the communities discussing this publication.

• Biomarkers, Tumor
• Exome Sequencing
• Leukemia, Lymphocytic, Chronic, B-Cell
• Mutation
• Prognosis